Tags

Type your tag names separated by a space and hit enter

In vitro evaluation of marketed antimalarial chloroquine phosphate tablets.
J Vector Borne Dis. 2005 Dec; 42(4):147-50.JV

Abstract

BACKGROUND & OBJECTIVES

The aim of the present study is to investigate the physicochemical equivalence of seven brands of tablets containing chloroquine phosphate, an antimalarial purchased from different retail pharmacy outlets.

METHODS

The quality and physicochemical equivalence of seven different brands of chloroquine phosphate tablets were assessed. The assessment included the evaluation of uniformity of weight, friability, crushing strength, disintegration and dissolution tests as well as chemical assay of the tablets.

RESULTS

All the seven brands of the tablets passed the British Pharmacopoeia (BP) standards for uniformity of weight, disintegration and crushing strength. One of seven brands failed the friability test. One of the brands did not comply with the standard assay of content of active ingredients. Dissolution test passes the pharmacopoeial standards for chloroquine phosphate tablets. There were no significant differences in the amounts of chloroquine phosphate released from the different brands.

INTERPRETATION & CONCLUSION

Out of the seven brands of anti-malarial chloroquine phosphate tablets only one brand fails to meet BP quality specifications which shows constant market monitoring of new products to ascertain their equivalency to pharmacopoeial standards.

Authors+Show Affiliations

Shri Sarvajanik Pharmacy College, Mehsana, India. amitk_31@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16457384

Citation

Patel, Amit K., et al. "In Vitro Evaluation of Marketed Antimalarial Chloroquine Phosphate Tablets." Journal of Vector Borne Diseases, vol. 42, no. 4, 2005, pp. 147-50.
Patel AK, Prajapati BG, Moria RS, et al. In vitro evaluation of marketed antimalarial chloroquine phosphate tablets. J Vector Borne Dis. 2005;42(4):147-50.
Patel, A. K., Prajapati, B. G., Moria, R. S., & Patel, C. N. (2005). In vitro evaluation of marketed antimalarial chloroquine phosphate tablets. Journal of Vector Borne Diseases, 42(4), 147-50.
Patel AK, et al. In Vitro Evaluation of Marketed Antimalarial Chloroquine Phosphate Tablets. J Vector Borne Dis. 2005;42(4):147-50. PubMed PMID: 16457384.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro evaluation of marketed antimalarial chloroquine phosphate tablets. AU - Patel,Amit K, AU - Prajapati,Bhupendra G, AU - Moria,Rubina S, AU - Patel,Chhaganbhai N, PY - 2006/2/7/pubmed PY - 2006/3/31/medline PY - 2006/2/7/entrez SP - 147 EP - 50 JF - Journal of vector borne diseases JO - J Vector Borne Dis VL - 42 IS - 4 N2 - BACKGROUND & OBJECTIVES: The aim of the present study is to investigate the physicochemical equivalence of seven brands of tablets containing chloroquine phosphate, an antimalarial purchased from different retail pharmacy outlets. METHODS: The quality and physicochemical equivalence of seven different brands of chloroquine phosphate tablets were assessed. The assessment included the evaluation of uniformity of weight, friability, crushing strength, disintegration and dissolution tests as well as chemical assay of the tablets. RESULTS: All the seven brands of the tablets passed the British Pharmacopoeia (BP) standards for uniformity of weight, disintegration and crushing strength. One of seven brands failed the friability test. One of the brands did not comply with the standard assay of content of active ingredients. Dissolution test passes the pharmacopoeial standards for chloroquine phosphate tablets. There were no significant differences in the amounts of chloroquine phosphate released from the different brands. INTERPRETATION & CONCLUSION: Out of the seven brands of anti-malarial chloroquine phosphate tablets only one brand fails to meet BP quality specifications which shows constant market monitoring of new products to ascertain their equivalency to pharmacopoeial standards. SN - 0972-9062 UR - https://www.unboundmedicine.com/medline/citation/16457384/In_vitro_evaluation_of_marketed_antimalarial_chloroquine_phosphate_tablets_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.